Sarepta's Q2 Earnings & Sales Beat Estimates, '26 Outlook Updated
Sarepta Therapeutics (SRPT) reported Q2 2026 adjusted EPS of 64 cents vs 58 cents expected, though down 68% YoY. Revenues were $401.3M, down 34% YoY, beating the $355.6M estimate, mainly due to lower Elevidys sales. SRPT narrowed 2026 net product revenue guidance to $1.2-$1.3B and raised collaboration revenue to $550-$600M. FDA accepted filings for full approvals of Vyondys 53 and Amondys 45.
How this was made
The 30-second read
Why it matters
This update combines an earnings beat with a guidance reset and multiple pipeline timing/regulatory milestones, creating a clear near-term catalyst set for SRPT positioning.
Market read
Traders get a same-day earnings and guidance catalyst plus concrete pipeline timing changes that can reprice risk into 2027 approval milestones.
What to watch
Contract manufacturing revenue changes and the absence of the prior-year Roche Japan milestone can mechanically lift collaboration revenue, so traders should separate recurring supply economics from one-off milestone effects.
Background
Sarepta’s commercial DMD portfolio includes PMO therapies (Exondys 51, Vyondys 53, Amondys 45) and Elevidys, with Elevidys shipments affected by prior safety concerns.
Ticker impact
Sarepta reported Q2 2026 EPS and revenue beats, narrowed 2026 guidance, and updated pipeline timelines for Elevidys and confirmatory approvals.
Likely supports upside bias post-earnings, but with volatility as Elevidys decline and delayed 12-week data temper the beat.
The article provides multiple fresh decision points: Q2 beat, 2026 guidance narrowing and collaboration revenue raise, plus a later-than-expected 1Q27 readout and FDA filing acceptance with a 2027 decision date.
Market effects
Reinforces the DMD gene-therapy commercialization sensitivity to safety-driven shipment decisions and revenue recognition timing.
Limited direct regional spillover; Japan milestone context is referenced but no new Japan regulatory action is disclosed.
Elevidys ex-U.S. commercialization rights and Roche-related manufacturing/collaboration flows highlight cross-border dependency in gene-therapy supply chains.
Counterpoint
The headline beat may be less durable because Elevidys revenues are still down sharply and the 12-week Cohort 8 data is pushed into 1Q27, extending uncertainty.
Key entities
- companySarepta Therapeutics, Inc.
SRPT; reported Q2 2026 results, updated 2026 guidance, and provided pipeline/regulatory timeline updates for DMD therapies.
- companyRoche Holding AG
RHHBY; referenced for a prior-year Japan milestone and for contract manufacturing and ex-U.S. marketing rights under the Elevidys licensing agreement.
- companyArrowhead Pharmaceuticals
ARWR; referenced as the partner in a multi-billion-dollar collaboration that supplied SRP-1001 and SRP-1003 programs.
- regulatorFDA
Accepted Sarepta’s filings to convert accelerated approvals for Vyondys 53 and Amondys 45 into full approvals, with a decision expected by Feb. 28, 2027.
